史上最全癌症靶向药.docx

1、史上最全癌症靶向药 癌症靶向药（2016）肺癌靶向药 疾病名称药物靶点靶向药物名称中国上市肺癌Her1 (EGFR, ErbB1)Gefitinib (吉非替尼)是Erlotinib (厄洛替尼)否Osimertinib(奥斯替尼AZD9291)Necitumumab (耐昔妥珠单抗)Afatinib (阿法替尼)Her2 (Neu, ErbB2)ALKCeritinib (赛丽替尼)Alectinib (爱乐替尼)Crizotinib (克唑替尼)是METROS1PD-1Nivolumab (纳武单抗)否Pembrolizumab (派姆单抗)VEGFR2Ramucirumab (雷莫芦单抗

2、)VEGFBevacizumab (贝伐珠单抗)是乳腺癌靶向药疾病名称药物靶点靶向药物名称中国上市乳腺癌CDK4Palbociclib (帕博西尼)否CDK6Her2 (Neu, ErbB2)Ado-trastuzumab emtansine(T-DM1)Pertuzumab (帕妥珠单抗)Trastuzumab (曲妥珠单抗)是Lapatinib (拉帕替尼)Her1 (EGFR, ErbB1)mTOREverolimus (依维莫司)结直肠癌靶向药 疾病名称药物靶点靶向药物名称中国上市结直肠癌Her1 (EGFR, ErbB1)Cetuximab (西妥西单抗)是Panitumumab (

3、帕尼单抗)否KIT, PDGFR, RAF, RET, VEGFR1/2/3Regorafenib (瑞格菲尼)VEGFA/BZiv-aflibercept (阿柏西普)PIGFVEGFR2Ramucirumab (雷莫芦单抗)VEGFBevacizumab (贝伐珠单抗)是白血病靶向药 疾病名称药物靶点靶向药物名称中国上市白血病KITImatinib (伊马替尼)是PDGFRABLNilotinib (尼洛替尼)Dasatinib (达沙替尼)Bosutinib (博舒替尼)否Ponatinib (普纳替尼)FGFR1-3FLT3VEGFR2BTKIbrutinib (伊鲁替尼)CD20Ob

4、inutuzumab (奥滨尤妥珠单抗)Ofatumumab (奥法木单抗)Rituximab (利妥西单抗)是CD52Alemtuzumab (阿伦单抗)否PI3KIdelalisibCD19BlinatumomabCD3BCL2Venetoclax淋巴瘤靶向药 疾病名称药物靶点靶向药物名称中国上市淋巴癌BTKIbrutinib (伊鲁替尼)否CD20Ibritumomab tiuxetan (替伊莫单抗)Rituximab (利妥西单抗)是Tositumomab (托西莫单抗)否Obinutuzumab (奥滨尤妥珠单抗)CD30Brentuximab vedotin (本妥西单抗)HDA

5、CBelinostat(贝利司他)Romidepsin (罗米地辛)Vorinostatt (伏立诺他)PI3KIdelalisibPD-1Nivolumab (纳武单抗)ProteasomeBortezomib (硼替佐米)是甲状腺癌靶向药 疾病名称药物靶点靶向药物名称中国上市甲状腺癌Her1 (EGFR, ErbB1), RET, VEGFR2Vandetanib (凡德他尼)否FLT3, KIT, MET, RET, VEGFR2Cabozantinib (卡博替尼)VEGFR2Lenvatinib (乐伐替尼)KIT, VEGFR, PDFGR, RAFSorafenib (索拉菲尼)

6、是黑色素瘤向药 疾病名称药物靶点靶向药物名称中国上市黑色素瘤PD-1Nivolumab (纳武单抗)否Pembrolizumab (派姆单抗)CTLA-4Lpilimumab (伊普利姆玛)BRAFVemurafenib (维罗非尼)Dabrafenib (达拉菲尼)MEKTrametinib (曲美替尼)Cobimetinib(卡比替尼)Aldesleukin(重组人白介素-2)是肾癌靶向药 疾病名称药物靶点靶向药物名称中国上市肾癌PD-1Nivolumab (纳武单抗)否VEGFR2Lenvatinib (乐伐替尼)Aldesleukin(重组人白介素-2)是mTORTemsirolimu

7、s (替西罗莫司)否VEGFR, PDGFR, KITPazopanib (帕唑帕尼)KIT, PDGFR, RAF, VEGFRSorafenib (索拉菲尼)是PDGFR/, VEGFR1/2/3, KIT, FLT3, RETSunitinib (舒尼替尼)VEGFBevacizumab (贝伐珠单抗)KIT, PDGFR, VEGFR1/2/3Axitinib (阿昔替尼)mTOREverolimus (依维莫司)FLT3, KIT, MET, RET, VEGFR2Cabozantinib (卡博替尼)否胃癌靶向药 疾病名称药物靶点靶向药物名称中国上市胃癌VEGFR2Ramuciru

8、mab (雷莫芦单抗)否HER2Trastuzumab (曲妥珠单抗)是胃肠道间质瘤靶向药 疾病名称药物靶点靶向药物名称中国上市胃肠道间质瘤KIT, PDGFR, RAF, RET, VEGFR1/2/3Regorafenib (瑞格菲尼)否ABL, PDGFR, KITImatinib (伊马替尼)是PDGFR/, VEGFR1/2/3, KIT, FLT3, RETSunitinib (舒尼替尼)肝癌靶向药 疾病名称药物靶点靶向药物名称中国上市肝癌VEGFRSorafenib (索拉菲尼)是PDGFRKITRAF食管胃结合部癌靶向药 疾病名称药物靶点靶向药物名称中国上市食管胃结合部癌VEG

9、FR2Ramucirumab (雷莫芦单抗)否Her2 (Neu, ErbB2)Trastuzumab (曲妥珠单抗)是多发性骨髓瘤靶向药 疾病名称药物靶点靶向药物名称中国上市多发性骨髓瘤HDACPanobinostat (帕比司他)否ProteasomeCarfilzomib (卡非佐米)Bortezomib (硼替佐米)是Ixazomib否CD38Daratumumab (达雷木单抗)SLAMF7(CS1/CD319/CRACC)Elotuzumab (埃罗妥珠单抗)胰腺癌靶向药 疾病名称药物靶点靶向药物名称中国上市胰腺癌EGFRCetuximab (西妥昔单抗)是Gefitinib (吉

10、非替尼)Erlotinib (厄洛替尼)否VEGFBevacizumab (贝伐珠单抗)是VEGFR, EGFRVandetanib (凡德他尼)否VEGFRSemaxanib (司马沙尼)妇科癌症靶向药 疾病名称药物靶点靶向药物名称中国上市卵巢癌PARPOlaparib (奥拉帕尼)否VEGFBevacizumab (贝伐珠单抗)是宫颈癌输卵管癌软组织肉瘤靶向药 疾病名称药物靶点靶向药物名称中国上市软组织肉瘤VEGFRPazopanib (帕唑帕尼)否PDGFRKIT其他癌症靶向药 疾病名称药物靶点靶向药物名称中国上市前列腺癌Sipueucel-T (前来腺癌治疗疫苗)否骨巨细胞瘤RANKLDenosumab (狄诺塞麦)基底细胞癌PTCHVismodegib (维莫德吉)SmoothenedSonidegib (索尼德吉)头颈癌Her1 (EGFR, ErbB1)Cetuximab (西妥西单抗)是高危神经母细胞瘤GD-2Dinutuximab否腹膜癌VEGFBevacizumab (贝伐珠单抗)是胶质母细胞瘤皮肤纤维肉瘤KITImatinib (伊马替尼)PDGFRABL